Please use this identifier to cite or link to this item:
Title: Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Authors: Rivera-Caravaca, José Miguel
Marín, Francisco
Esteve-Pastor, María Asunción
Raña-Míguez, Paula
Anguita, Manuel
Muñiz, Javier
Cequier, Ángel
Bertomeu-Martínez, Vicente
Valdés, Mariano
Vicente, Vicente
Lip, Gregory Yoke Hong
Roldán, Vanessa
metadata.dc.subject.mesh: Aged
Aged, 80 and over
Atrial Fibrillation
Follow-Up Studies
Ischemic Attack, Transient
Retrospective Studies
Risk Assessment
Risk Factors
Issue Date: 19-Sep-2017
Abstract: We investigated the incidence of nonembolic adverse events in 2 cohorts of patients with atrial fibrillation (AF) and validated the 2MACE score ([metabolic syndrome, age ≥75] [doubled]; [myocardial infarction or revascularization, congestive heart failure {HF}, and stroke, transient ischemic attack or thromboembolism]) as predictor of major adverse cardiovascular events (MACEs). We recruited 2,630 patients with AF from 2 different cohorts (Murcia AF and FANTASIIA). The 2MACE score was calculated, and during a median of 7.2 years (Murcia AF cohort) and 1.01 years (FANTASIIA) of follow-up, we recorded all nonembolic adverse events and MACEs (composite of nonfatal myocardial infarction or revascularization and cardiovascular death). Receiver operating characteristic curves comparison, reclassification and discriminatory analyses, and decision curve analyses were performed to compare predictive ability and clinical usefulness of the 2MACE score against CHA2DS2-VASc. During follow-up, there were 65 MACEs in the Murcia cohort and 60 in the FANTASIIA cohort. Events rates were higher in the high-risk category (score ≥3) (1.94%/year vs 0.81%/year in the Murcia cohort; 6.01%/year vs 1.71%/year, in FANTASIIA, both p 
metadata.dc.identifier.doi: 10.1016/j.amjcard.2017.09.003
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons